Member of the Association of American Physicians
Mycobacterium tuberculosis, Tuberculosis, Microbiology, Virology and Gene are his primary areas of study. His Mycobacterium tuberculosis study incorporates themes from Antibacterial agent, Mutant, Immunology, Disease and Virulence. He works in the field of Tuberculosis, namely Isoniazid.
In his study, Complementation is strongly linked to Sigma factor, which falls under the umbrella field of Microbiology. The concepts of his Virology study are interwoven with issues in Gene expression profiling, Central nervous system, Pattern recognition receptor and Cytosol. His Pharmacology research is multidisciplinary, relying on both Moxifloxacin, Ethambutol and SQ109.
The scientist’s investigation covers issues in Mycobacterium tuberculosis, Tuberculosis, Microbiology, Immunology and Virology. The Mycobacterium tuberculosis study combines topics in areas such as In vitro, Antibacterial agent, Immune system, Gene and Drug resistance. The Gene study which covers Molecular biology that intersects with Plasmid and Regulation of gene expression.
William R. Bishai interconnects Internal medicine, Pharmacology and In vivo in the investigation of issues within Tuberculosis. The various areas that William R. Bishai examines in his Microbiology study include Bacteria, Mutant and Virulence. His studies deal with areas such as Tuberculin and Disease as well as Immunology.
William R. Bishai mostly deals with Tuberculosis, Mycobacterium tuberculosis, Cancer research, Immune system and Immunology. His Tuberculosis research is mostly focused on the topic Mycobacterium africanum. His Mycobacterium tuberculosis research integrates issues from Potency, Microbiology and Cytotoxicity.
Microbiology and Virulence are frequently intertwined in his study. His studies in Cancer research integrate themes in fields like Agonist, Cytotoxic T cell, Cancer and Fusion protein. William R. Bishai combines subjects such as Disease progression and Inhibitory postsynaptic potential with his study of Immunology.
His primary scientific interests are in Tuberculosis, Mycobacterium tuberculosis, Cancer research, Microbiology and Immunology. His Tuberculosis study combines topics in areas such as Transmission, Drug resistance and In vivo. William R. Bishai focuses mostly in the field of Mycobacterium tuberculosis, narrowing it down to topics relating to Immune system and, in certain cases, Antigen and RNA.
His work carried out in the field of Cancer research brings together such families of science as Suppressor, Bacterial clearance and Cancer immunotherapy. His study on Pathogen is often connected to Phosphoproteomics as part of broader study in Microbiology. His study in Immunology is interdisciplinary in nature, drawing from both Acquired immunodeficiency syndrome and Myeloid-derived Suppressor Cell.
This overview was generated by a machine learning system which analysed the scientist’s body of work. If you have any feedback, you can contact us here.
Community-acquired meticillin-resistant Staphylococcus aureus: an emerging threat.
Nicola Zetola;John S Francis;Eric L Nuermberger;William R Bishai.
Lancet Infectious Diseases (2005)
Whole-Genome Comparison of Mycobacterium tuberculosis Clinical and Laboratory Strains
R. D. Fleischmann;D. Alland;Jonathan A Eisen;L. Carpenter.
Journal of Bacteriology (2002)
Mechanisms of latency in Mycobacterium tuberculosis
Nikki M Parrish;James D Dick;William R Bishai.
Trends in Microbiology (1998)
Fluoroquinolones, tuberculosis, and resistance
Amy Sarah Ginsburg;Jacques H Grosset;William R Bishai.
Lancet Infectious Diseases (2003)
Diagnostic point-of-care tests in resource-limited settings
Paul K Drain;Emily P Hyle;Farzad Noubary;Farzad Noubary;Farzad Noubary;Kenneth A Freedberg.
Lancet Infectious Diseases (2014)
Comparison of a Whole-Blood Interferon γ Assay With Tuberculin Skin Testing for Detecting Latent Mycobacterium tuberculosis Infection
Gerald H. Mazurek;Philip A. LoBue;Philip A. LoBue;Charles L. Daley;John Bernardo.
A postgenomic method for predicting essential genes at subsaturation levels of mutagenesis: Application to Mycobacterium tuberculosis
Gyanu Lamichhane;Matteo Zignol;Natalie J. Blades;Deborah E. Geiman.
Proceedings of the National Academy of Sciences of the United States of America (2003)
Moxifloxacin-containing Regimen Greatly Reduces Time to Culture Conversion in Murine Tuberculosis
Eric L. Nuermberger;Tetsuyuki Yoshimatsu;Sandeep Tyagi;Richard J. O'Brien.
American Journal of Respiratory and Critical Care Medicine (2004)
Moxifloxacin versus ethambutol in the initial treatment of tuberculosis: a double-blind, randomised, controlled phase II trial
Marcus B Conde;Anne Efron;Carla Loredo;Gilvan R Muzy De Souza.
The Lancet (2009)
Latent Mycobacterium tuberculosis-persistence, patience, and winning by waiting.
Yukari C. Manabe;William R. Bishai.
Nature Medicine (2000)
If you think any of the details on this page are incorrect, let us know.
We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below: